However, in cases where patients with prostate adenocarcinoma progress to the rare prostate sarcomatoid carcinoma under regular endocrine therapy without an increase in PSA levels, physicians may be misled into believing the adenocarcinoma is controlled, thereby masking the disease’s actual progression. Here, KLK3 is linked to prostate adenocarcinoma.